Wellington Management Group
TBPH icon

Wellington Management Group’s Theravance Biopharma TBPH Stock Holding History

Wellington Management Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Buy
113,481
+3,781
+3% +$62.6K ﹤0.01% 1635
2026
Q1 		$1.78M Sell
109,700
-13,265
-11% -$235K ﹤0.01% 1574
2025
Q4 		$2.3M Sell
122,965
-7,186
-6% -$119K ﹤0.01% 1566
2025
Q3 		$1.9M Sell
130,151
-37,278
-22% -$471K ﹤0.01% 1647
2025
Q2 		$1.85M Buy
167,429
+12,000
+8% +$117K ﹤0.01% 1595
2025
Q1 		$1.39M Sell
155,429
-43,062
-22% -$401K ﹤0.01% 1635
2024
Q4 		$1.87M Buy
198,491
+7,162
+4% +$65.2K ﹤0.01% 1583
2024
Q3 		$1.54M Sell
191,329
-159,258
-45% -$1.38M ﹤0.01% 1617
2024
Q2 		$2.97M Buy
350,587
+19,625
+6% +$177K ﹤0.01% 1430
2024
Q1 		$2.97M Buy
330,962
+43,860
+15% +$406K ﹤0.01% 1445
2023
Q4 		$3.23M Buy
287,102
+116,164
+68% +$1.17M ﹤0.01% 1401
2023
Q3 		$1.48M Sell
170,938
-11,322
-6% -$109K ﹤0.01% 1534
2023
Q2 		$1.89M Buy
182,260
+41,999
+30% +$464K ﹤0.01% 1489
2023
Q1 		$1.52M Sell
140,261
-3,171
-2% -$33.5K ﹤0.01% 1562
2022
Q4 		$1.61M Sell
143,432
-8,078
-5% -$84.9K ﹤0.01% 1547
2022
Q3 		$1.54M Buy
151,510
+4,042
+3% +$37.9K ﹤0.01% 1575
2022
Q2 		$1.34M Sell
147,468
-919
-0.6% -$8.47K ﹤0.01% 1618
2022
Q1 		$1.42M Sell
148,387
-49,667
-25% -$487K ﹤0.01% 1675
2021
Q4 		$2.19M Sell
198,054
-52,165
-21% -$455K ﹤0.01% 1643
2021
Q3 		$1.85M Sell
250,219
-8,477,105
-97% -$94.8M ﹤0.01% 1695
2021
Q2 		$127M Buy
8,727,324
+1,263,122
+17% +$23.7M 0.02% 568
2021
Q1 		$152M Buy
7,464,202
+1,996,902
+37% +$38M 0.03% 487
2020
Q4 		$97.2M Buy
5,467,300
+739,708
+16% +$13.3M 0.02% 598
2020
Q3 		$69.9M Buy
4,727,592
+244,815
+5% +$4.59M 0.01% 606
2020
Q2 		$94.1M Buy
4,482,777
+315,254
+8% +$8.1M 0.02% 541
2020
Q1 		$96.3M Buy
4,167,523
+989,986
+31% +$24.8M 0.03% 467
2019
Q4 		$82.3M Buy
+3,177,537
New +$61.8M 0.02% 615
2016
Q4 		– Sell
-190,950
Closed -$6.92M – 2266
2016
Q3 		$6.92M Buy
+190,950
New +$5.32M ﹤0.01% 1287

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wellington Management Group's TBPH Position: Q2 2026 in Review

Wellington Management Group increased its Theravance Biopharma (TBPH) stake by 3.4% in Q2 2026, buying an estimated $62.6K and bringing the position to 113,481 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

Wellington Management Group first reported a position in TBPH in Q3 2016 and has held it in 28 quarters since. The position peaked at $152M in Q1 2021. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Wellington Management Group held 113,481 shares of Theravance Biopharma worth $1.93M as of Q2 2026.
  • Wellington Management Group bought 3,781 Theravance Biopharma shares in Q2 2026, an estimated $62.6K.
  • Theravance Biopharma made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1635 holding.
  • Wellington Management Group first reported a position in Theravance Biopharma in Q3 2016 and has held it in 28 quarters since.
  • Wellington Management Group's Theravance Biopharma position peaked at $152M in Q1 2021.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.